Gene therapy improves immune function in preadolescents with X-linked severe combined immunodeficiency

Blood

Volumn 110, Issue 1, 2007, Pages 67-73

  Chinen, Javier ^a   Davis, Joie ^a   De Ravin, Suk See ^b   Hay, Beverly N ^a   Hsu, Amy P ^a   Linton, Gilda F ^b   Naumann, Nora ^b   Nomicos, Effie Y H ^b   Silvin, Christopher ^a   Ulrick, Jean ^b   Whiting Theobald, Narda L ^b   Malech, Harry L ^b   Puck, Jennifer M ^a  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIVIRUS AGENT; CD34 ANTIGEN; IMMUNOGLOBULIN; INTERLEUKIN 2 RECEPTOR GAMMA; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RETROVIRUS VECTOR;

ADOLESCENCE; ADOLESCENT; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW TRANSPLANTATION; CASE REPORT; CELL FUNCTION; CHILD; COMBINED IMMUNODEFICIENCY; DRUG EFFICACY; DRUG SAFETY; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; MALE; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; T LYMPHOCYTE; VIRAL GENE THERAPY; X CHROMOSOME LINKED DISORDER;

EID: 34347376929     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-11-058933     Document Type: Article

References (32)

1. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science. 2000;288:669-672.
2. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science. 2003;302:415-419.
3. Gaspar HB, Parsley KL, Howe S, et al. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet. 2004;364:2181-2187.
4. Puck JM. X-linked severe combined immunodeficiency. In: Ochs H, Smith CIE, Puck JM, eds. Primary Immunodeficiency Diseases, a Molecular and Genetic Approach. 2nd ed. New York, NY: Oxford University Press; 2007:123-136.
5. Buckley RH, Schiff SE, Schiff RI, et al. Hematopoietic stem cell transplantation for the treatment of severe combined immunodeficiency. New Engl J Med. 1999;340:508-516.
6. Haddad E, Landais P, Friedrich W, et al. Long term immune reconstitution and outcome after HLA-nonidentical T-cell depleted bone marrow transplantation for severe combined immunodeficiency: a European retrospective study of 116 patients. Blood. 1998;91:3646-3653.
7. Antoine C, Muller S, Cant A, et al. Long-term survival and transplantation of hematopoietic stem cells for immunodeficiencies: report of the European experience 1968-1999. Lancet. 2003;361:553-556.
8. Myers LA, Patel DD, Puck JM, Buckley RH. Hematopoietic stem cell transplantation for SCID in the neonatal period leads to superior thymic output and improved survival. Blood. 2002;99:872-878.
9. Buckley RH, Fischer A. Bone marrow transplantation for primary immunodeficiency diseases. In: Ochs H, Smith CIE, Puck JM, eds. Primary Immunodeficiency Diseases, a Molecular and Genetic Approach. 2nd ed. New York, NY: Oxford University Press; 2007:669-687.
10. Smogorzewska EM, Brooks J, Annett G, et al. T cell depleted haploidentical bone marrow transplantation for the treatment of children with severe combined immunodeficiency. Arch Immunol Ther Exp (Warsz). 2000;48:111-118.
11. Haddad E, LeDeist F, Aucouturier P, et al. Longterm chimerism and B-cell function after bone marrow transplantation in patients with severe combined immunodeficiency with B cells: a single center study of 22 patients. Blood. 1999;94:2923-2930.
12. Cole BO, Welbury RR, Bond E, Abinum M. Dental manifestations in severe combined immunodeficiency following bone marrow transplantation. Bone Marrow Transplant. 2000;25:1007-1009.
13. Slatter MA, Gennery AR, Cheetham TD, et al. Thyroid dysfunction after bone marrow transplantation for primary immunodeficiency without the use of total body irradiation in conditioning. Bone Marrow Transplant. 2004;33:949-953.
14. Clement-DE Boers A, Oosrdijk W, Van Weel-Sipman MH, Van den Broeck J, Wit JM, Vossen JM. Final height and hormonal function after bone marrow transplantation in children. J Pediatr. 1996;129:544-550.
15. Cavazzana-Calvo M, Lagresle C, Hacein-Bey-Albina S, Fischer A. Gene therapy for severe combined immunodeficiency. Annu Rev Med. 2005;56:585-602.
16. Gray JT, Hacein-Bey-Albina S, Cavazzana-Calvo M, Fischer A. The effect of the B2 mutation on hematopoietic reconstitution in the French XSCID gen therapy trial. Mol Ther. 2006;13(suppl 1):S254.
17. Tsai EJ, Malech HL, Kirby MR, et al. Retroviral transduction of IL2RG into CD34(+) cells from X-linked severe combined immunodeficiency patients permits human T- and B-cell development in sheep chimeras. Blood. 2002;100:72-79.
18. Roesler J, Brenner S, Bukovsky AA, et al. Third-generation, self-inactivating gp91(phox) lentivector corrects the oxidase defect in NOD/SCID mouse-repopulating peripheral blood-mobilized CD34+ cells from patients with X-linked chronic granulomatous disease. Blood. 2002;100:4381-4390.
19. Horwitz ME, Barrett AJ, Brown MR, et al. Treatment of chronic granulomatous disease with non-myeloablative conditioning and a T-cell-depleted hematopoietic allograft. N Engl J Med. 2001;344:881-888.
20. Lyons AB. Analysing cell division in vivo and in vitro using flow cytometric measurement of CFSE dye dilution. J Immunol Methods. 2000;243:147-154.
21. Douek DC, McFarland RD, Keiser PH, et al. Changes in thymic function with age and during the treatment of HIV infection. Nature. 1998;396:690-695.
22. Sarzotti M, Patel DD, Li X, et al. T cell repertoire development in humans with SCID after nonablative allogeneic marrow transplantation. J Immunol. 2003;170:2711-2718.
23. Schmidt M, Glimm H, Lemke N, et al. A model for the detection of clonality in marked hematopoietic stem cells. Ann N Y Acad Sci. 2001;938:146-155.
24. Schmidt M, Zickler P, Hoffmann G, et al. Polyclonal long-term repopulating stem cell clones in a primate model. Blood. 2002;100:2737-2743.
25. Wu X, Li Y, Crise B, Burgess SM. Transcription start regions in the human genome are favored targets for MLV integration. Science. 2003;300:1749-1751.
26. Puck JM, Pepper AE, Henthorn PS, et al. Mutation analysis of IL2RG in human X-linked severe combined immunodeficiency. Blood. 1997;89:1968-1977.
27. Malech HL, Maples PB, Whiting-Theobald N, et al. Prolonged production of NADPH oxidase-corrected granulocytes following gene therapy of chronic granulomatous disease. Proc Natl Acad Sci U S A. 1997;94:12133-12138.
28. Malech HL. Use of serum-free medium with fibronectin fragment enhanced transduction in a system of gas permeable plastic containers to achieve high levels of retrovirus transduction at clinical scale. Stem Cells. 2000;18:155-156.
29. Malech HL, Brenner S, Choi U. Progress toward effective gene therapy for chronic granulomatous disease. Jpn J Inf Dis. 2004;57:S27-S28.
30. + cells with lymphomyeloid differentiation potential and self-renewal capacity in the SCID-X1 gene therapy trial. Blood. 2005;105:2699-2706.
31. Wu X, Luke BT, Burgess SM. Redefining the common integration site. Virology. 2006;344:292-295.
32. Thrasher AJ, Hacein-Bey-Abina S, Gaspar HB, et al. Failure of SCID-X1 gene therapy in older patients. Blood. 2005;105:4255-4257.